摘要
目的回顾性分析301例非小细胞肺癌(NSCLC)组织表皮生长因子受体(EGFR)基因突变检测结果,比较三种实验方法检查EGFR突变的差异。探讨肺癌临床靶向个体化治疗进行EGFR分子病理检查的最佳方法。方法应用聚合酶链反应(PCR)结合直接测序法检测171例肺癌DNA样本;TaqMan探针荧光定量PCR法检测88例肺癌DNA样本;扩增阻碍突变系统(ARMS)法检测42例肺癌DNA样本。结果 PCR直接测序法、TaqMan探针荧光定量PCR法、ARMS法的阳性总检出率分别是31.58%、27.27%、42.86%。结论 PCR直接测序法和TaqMan探针荧光定量PCR法阳性总检出率差异无统计学意义(P>0.05),ARMS法阳性总检出率高于PCR直接测序法和TaqMan探针荧光定量PCR法(P均<0.01)。对于不同来源的肺癌组织标本,不同方法检测EGFR突变具有各自的优点和不足。
Objective The results of epidermal growth factor receptor （EGFR） mutations in 301 tis- sues with non-small cell lung cancer （NSCLC） detected by three different methods were respectively analyzed. The differences among three methods were compared. The objective of this study was to explore the proper mo- lecular method for personalized target therapy in lung cancer. Methods Polymerase chain reaction combine with direction sequencing was used to detect EGFR mutations in 171 patients. Real-time PCR with TaqMan fluo- recent probe was used to detect EGFR mutations in 88 patients and amplification refractory mutation system PCR （ARMS-PCR） was used to detect EGFR mutations in 42 patients. Results The total positive rates for sequen- cing,TaqMan real-time PCR, and ARMS-PCR methods were 31.58% , 27.27% , and 42.86% respectively. Conclusion No significant difference in total positive rate between direct sequencing and TaqMan real-time PCR （P 〉 0.05）. The total positive rate was higher in ARMS-PCR than that in direct sequencing and TaqMan real-time PCR （P 〈 0.01 ）. To different tissues, different methods have their superiority when used for detection of EGFR mutations in lung cancer.
出处
《东南国防医药》
2012年第5期387-389,共3页
Military Medical Journal of Southeast China
基金
国家自然科学基金(30970813
81171391)
